Deployment of Teleconsulting in Geriatric Oncology for Older Patients
Launched by ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE · Nov 9, 2022
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how telemedicine, or virtual doctor visits, can help older cancer patients receive better care. The focus is on patients aged 75 and older who are being treated for various types and stages of cancer. The goal is to see if using teleconsultations with geriatric specialists can reduce the number of patients who need to be readmitted to the hospital within three months after treatment. Participants will be divided into two groups: one will receive standard cancer care, while the other will get a comprehensive assessment through a teleconsultation, which includes a review of their medications to avoid any harmful side effects.
To be eligible for the study, patients must be 75 years or older, agree to the geriatric assessment, and be able to provide consent. Patients with severe cognitive impairment or communication difficulties may not qualify. Those who participate will have the chance to work with healthcare professionals from different hospitals through telemedicine, making it easier for them to access specialized care, especially in areas where these services are limited. The trial aims not only to improve patient outcomes but also to understand how this approach can ease the burden on healthcare resources and improve patient satisfaction.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients 75 years and older
- • Suffering from all types and all stages of cancer and treated for cancer in participating centers
- • G8 (screening tool) ≤ 14/17
- • Agreeing to benefit from a geriatric oncology assessment
- • Having signed a consent
- • Affiliated to French social security or a similar French solidarity scheme
- Exclusion Criteria:
- • Patients under guardianship or curatorship or inability to sign consent
- • Patients with severe cognitive impairment (MMSE \< 10/30)
- • Patients with severe hearing or visual impairments as these patients will have difficulty performing the telemedicine consultation
- • Patients with a significant language barrier without an interpreter present because these patients will have difficulty carrying out the Telemedicine consultation
- • Patients with expectancy less than 3 months
About Assistance Publique Hopitaux De Marseille
Assistance Publique - Hôpitaux de Marseille (AP-HM) is a leading public healthcare institution in France, dedicated to providing high-quality medical care and advancing research in various clinical fields. As a prominent sponsor of clinical trials, AP-HM is committed to fostering innovation and improving patient outcomes through rigorous scientific investigation. With a multidisciplinary approach, the institution collaborates with a network of healthcare professionals, researchers, and academic partners to facilitate cutting-edge studies that address critical health challenges. AP-HM's dedication to ethical standards and patient safety underscores its role as a trusted leader in clinical research and healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Avignon, , France
Patients applied
Trial Officials
Anne-Laure COUDERC
Principal Investigator
Assistance Publique des Hôpitaux de Marseille (AP-HM)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials